Description
100 milligrams. For the treatment of patients with type 2 diabetes mellitus, ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2, and sitagliptin, an inhibitor of dipeptidyl peptidase-4, were combined into an oral fixed-dose combination (FDC) tablet.




Reviews
There are no reviews yet.